)
Omeros (OMER) investor relations material
Omeros Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
YARTEMLEA Q3 gross revenue was $41.8 million, up 29.6% QoQ; net sales were $35.9 million, up 26%.
Operating cash flow was positive for a second consecutive quarter at $13.3 million; cash and short-term investments totaled $95.3 million.
Operating income was $4.5 million, while GAAP net loss was $57.4 million, primarily due to a $62.0 million non-cash derivative remeasurement loss.
Financial highlights
Adjusted net income, excluding non-cash fair-value remeasurement, was $4.7 million, or $0.06 per share, versus $1.8 million, or $0.02 per share, in Q2.
Q3 net product sales were $35.9 million; 9M sales were $74.4 million. Gross-to-net adjustments were 14.0% in Q3 and 12.7% for 9M.
Q3 R&D was $16.1 million and SG&A was $14.5 million; 9M operating loss narrowed to $12.8 million from $93.7 million.
9M operating cash flow was $2.9 million, versus cash used of $76.3 million in 9M 2025.
Q3 GAAP loss per share was $0.79; 9M net income was $11.9 million versus a $89.8 million loss in 9M 2025.
Outlook and guidance
Q4 R&D is expected to exceed Q3, led by YARTEMLEA, other MASP-2 programs, and ONCOTOX-AML; SG&A is expected to be slightly higher with commercial expansion.
Q4 interest expense is expected to be comparable to Q3; income from discontinued operations is expected at $5 million-$6 million, excluding non-cash OMIDRIA royalty-asset remeasurement.
YARTEMLEA revenue momentum continued into Q4; 2027 guidance will follow when there is greater sales visibility. Cash and expected sales are expected to fund more than 12 months of operations.
OMS527 patient-trial enrollment is expected in Q1 2027 after an additional FDA-requested nonclinical study; OMS805 Phase 1b is targeted for late 2027.
- YARTEMLEA's rapid U.S. uptake fueled strong Q2 sales, net income, and liquidity, despite EU hurdles.OMER
Q2 2026 - All proposals passed as YARTEMLEA launch and pipeline advances marked a transformative year.OMER
AGM 2026 - YARTEMLEA launch drove $9.9M sales, $56.1M net income, and strong liquidity in Q1 2026.OMER
Q1 2026 - FDA approval, asset sale, and strengthened governance drive major 2025 milestones.OMER
Proxy filing - Major asset sale and YARTEMLEA launch drove profitability and rapid market adoption.OMER
Q4 2025 - FDA approved YARTEMLEA for TA-TMA, launching January 2026 with strong efficacy and safety.OMER
FDA Announcement - Q3 net loss narrowed to $32.2M, pipeline advanced, but going concern risk persists.OMER
Q3 2024 - Q2 net loss rose on one-time costs; debt cut, OMIDRIA royalties up, clinical pipeline advanced.OMER
Q2 2024 - Net loss narrowed to $33.5M as debt restructuring and narsoplimab launch took priority.OMER
Q1 2025
)
)
)
)
)
)
)
)